Gosebruch Henry O — SEC insider filings
SEC reporting owner CIK 1659625. 20 insider filings on record with FilingPulse; latest filed 2026-08-27.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2020-10-02 to 2026-08-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 65,000 shares, $1,089,370 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 15 legs across 6 filings — 272,920 shares, $39,590,859 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 31.
- Largest priced transaction: sale of 83,960 shares @ $155.00 ($13,013,800) in AbbVie Inc., filed 2022-05-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | EVP, Chief Strategy Officer | 10 | — | 15 legs · 272,920 sh · $39,590,859 | 18 |
| ACELYRIN, Inc. (SLRN) | Director | 3 | 1 leg · 50,000 sh · $900,000 | — | 6 |
| Neumora Therapeutics, Inc. (NMRA) | President & CEO, Director | 2 | 1 leg · 15,000 sh · $189,370 | — | 2 |
| Aptinyx Inc. (APTX) | Director | 4 | — | — | 4 |
| ANI PHARMACEUTICALS INC (ANIP) | Director | 1 | — | — | 1 |
Insider filings — Gosebruch Henry O
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-27 | 4 | ANI PHARMACEUTICALS INC (ANIP) | Grant/award (A): 6,662 @ $0 | EDGAR |
| 2025-05-23 | 4 | ACELYRIN, Inc. (SLRN) | Disposition to issuer (D): 50,000 · Disposition to issuer (D): 92,158 (derivative) · Disposition to issuer (D): 155,450 (derivative) | EDGAR |
| 2024-06-11 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 92,158 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 80,000 @ $0 · Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2023-09-19 | 4 | Neumora Therapeutics, Inc. (NMRA) | Purchase (P): 15,000 @ $12.62 | EDGAR |
| 2023-05-11 | 4 | ACELYRIN, Inc. (SLRN) | Purchase (P): 50,000 @ $18 · Other (J): 155,450 (derivative) @ $0 · Other (J): 155,450 (derivative) @ $0 | EDGAR |
| 2022-05-31 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4/A | AbbVie Inc. (ABBV) | Sale (S): 15,733 @ $146.81 · Sale (S): 5,167 @ $147.60 · Sale (S): 4,000 @ $148.71 · Sale (S): 100 @ $149.38 | EDGAR |
| 2022-05-20 | 4/A | AbbVie Inc. (ABBV) | Option exercise (M): 83,960 @ $54.86 · Sale (S): 83,960 @ $155 · Option exercise (M): 83,960 (derivative) @ $54.86 | EDGAR |
| 2022-05-18 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 83,960 @ $54.86 · Sale (S): 83,960 @ $155 · Option exercise (M): 83,960 (derivative) @ $54.86 | EDGAR |
| 2022-03-02 | 4 | AbbVie Inc. (ABBV) | Sale (S): 15,733 @ $146.81 · Sale (S): 5,167 @ $147.60 · Sale (S): 4,000 @ $148.71 · Sale (S): 100 @ $149.38 | EDGAR |
| 2022-03-01 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 30,156 @ $149.54 · Sale (S): 5,596 @ $147.54 · Sale (S): 8,303 @ $148.62 · Sale (S): 1,101 @ $149.14 | EDGAR |
| 2022-02-22 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 36,673 @ $0 · Grant/award (A): 7,972 @ $0 · Grant/award (A): 14,722 @ $0 · Grant/award (A): 8,701 @ $0 · Grant/award (A): 30,647 (derivative) @ $0 | EDGAR |
| 2021-09-10 | 4 | AbbVie Inc. (ABBV) | Gift (G): 30,000 @ $0 · Gift (G): 30,000 @ $0 | EDGAR |
| 2021-06-01 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-03-02 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 22,833 @ $107.74 | EDGAR |
| 2021-02-22 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 22,287 @ $0 · Grant/award (A): 6,555 @ $0 · Grant/award (A): 7,972 @ $0 · Grant/award (A): 14,724 @ $0 · Grant/award (A): 49,068 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 5,339 (derivative) @ $2.22 | EDGAR |
| 2020-11-24 | 4 | AbbVie Inc. (ABBV) | Sale (S): 6,900 @ $98.83 · Sale (S): 33,100 @ $99.49 | EDGAR |
| 2020-10-02 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 5,490 (derivative) @ $2.16 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1659625 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs